European medical regulators announced that European countries should decide on their own how to use AstraZeneca based on their infection rates and the availability of alternative vaccines.
Several European countries have announced that due to the occurrence of rare blood clots, the use of AstraZeneca is restricted in young people, most of which occur in women under 60 within two weeks of vaccination.
However, the European Medicines Agency (EMA) did not make recommendations, stating that countries should assess risks by themselves based on local conditions, which vary greatly within the EU.
“We try to provide as much information as possible about the benefits and risks that have been identified, and based on this and the pandemic situation in the member states-infection rates, availability of different vaccines-member states can make differences on who gets vaccinated. Decision,” EMA Emer Cooke said at the briefing.
Cook said the risk of death from covid-19 is “much higher” than the risk of death due to rare side effects.
Cook said: “It is very important to use vaccines and defeat this pandemic.”
Sabine Straus, chairman of the EMA safety committee, said the side effects are not unexpected.
Straus added that by April 4, EMA had received reports of 169 cases of rare brain blood clots or 34 million doses of cerebral venous sinus thrombosis (CVST) in the European Economic Area (EEA).
EMA data analysis officer Peter Arlett said three cases of low platelet blood clots were also reported after Johnson & Johnson vaccination. Experts told Reuters that it is too early to say whether these cases are related to the vaccine.
AstraZeneca said that after regulators announced that blood clots in the brain should be listed as a rare side effect of the vaccine, the company is working with European and British regulators to exchange information about its covida-19 vaccine.
AstraZeneca pointed out: “Both of the above-mentioned views confirm that this vaccine has a high protective effect against all severity of covida-19, and these benefits still far outweigh the risks.”
The statement added: “However, they concluded that these events may be related to the vaccine and requested that they be listed as extremely rare side effects. AstraZeneca is actively working with regulatory agencies to change product information.”